Close Menu

Amgen

The Nasdaq notice comes several months after the firm was almost delisted from the market.

Beyond studying European genetic structural variation, Estonian Genome Project Director Andres Metspalu envisions using the tens of thousands of samples collected so far to better inform healthcare decisions in Estonia, and sees increasing opportunities to take part in drug development activities.

As the first consumer to receive his genome through Illumina's individual genome-sequencing service, Hermann Hauser received his results at an Aug. 20 ceremony at Illumina's San Diego headquarters.

"If approved by the FDA, the DxS TheraScreen: K-RAS Mutation Kit would become a companion diagnostic for use with Erbitux in metastatic colorectal cancer to determine which patients have wild-type KRAS status in the US," DxS said this week.

Pairings: Sep 2, 2009

Premium

Michael Snyder, Earl Collier, Christian Henry, Leroy Hood, George Church

People in the News: Sep 1, 2009

Premium

Jon Faiz Kayyem, James White, Chris Gleeson, Mark Lappe, Francois Mandeville, Earl Collier, David Barker, Lynne Kielhorn

The suit claimed that Amgen infringed UI patents related to a cytomegalovirus promoter by manufacturing its billion-dollar blockbuster anti-inflammatory Enbrel and moncoclonal antibody Vectibix.

A working group led by the NIH and CDC issued five recommendations to "enhance the foundation" for using personal genomics to improve health.

A Phase III prospective study shows Vectibix combined with an irinotecan-based chemotherapy regimen improves progression-free survival in patients with wild-type KRAS tumors compared to chemotherapy alone. The study did not reach statistical significance for showing improvement in overall survival, however.

The firm's revenues fell 61 percent, but it cut its net loss 28 percent on lower spending. Decode also cautioned that it has sufficient cash resources to fund its operations only into the second half of its third quarter.

Pages

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.